Financial Lp Hrt Sells 34,938 Shares of Bluejay Diagnostics (NASDAQ:BJDX) Stock

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) major shareholder Financial Lp Hrt sold 34,938 shares of the company’s stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $1.40, for a total value of $48,913.20. Following the completion of the sale, the insider owned 92,055 shares in the company, valued at $128,877. The trade was a 27.51% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Thursday, July 9th, Financial Lp Hrt bought 64,047 shares of Bluejay Diagnostics stock. The shares were purchased at an average cost of $1.51 per share, with a total value of $96,710.97.

Bluejay Diagnostics Stock Down 15.9%

Bluejay Diagnostics stock traded down $0.23 during mid-day trading on Monday, hitting $1.22. 973,437 shares of the stock were exchanged, compared to its average volume of 1,803,857. Bluejay Diagnostics, Inc. has a 12 month low of $1.03 and a 12 month high of $16.68. The firm’s fifty day simple moving average is $2.69 and its two-hundred day simple moving average is $2.49. The stock has a market capitalization of $1.26 million, a price-to-earnings ratio of -0.10 and a beta of 0.88.

Bluejay Diagnostics (NASDAQ:BJDX) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.95) EPS for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Bluejay Diagnostics currently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Bluejay Diagnostics

An institutional investor recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC acquired a new position in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned 9.15% of Bluejay Diagnostics as of its most recent SEC filing. 18.47% of the stock is currently owned by institutional investors and hedge funds.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.